Biopharma PEG Scientific Inc.

Biopharma PEG, a key provider of premium polyethylene glycol (PEG) derivatives, is thrilled to announce a substantial expansion of its large-scale Good Manufacturing Practice (GMP) production capabilities.

Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields.

Biopharma PEG, a top supplier of PEG derivatives, is excited to introduce its new line of monodispersed PEGs. These specially sized polymers are designed to improve the stability and delivery of proteins and peptides in drugs.

Biopharma PEG, a leading provider of advanced polyethylene glycol (PEG) derivatives, is excited to announce its participation in the BIO International Convention 2024, scheduled to take place from June 3-6, 2024, at the San Diego Convention Center.

Biopharma PEG Scientific Inc., a pioneering biotechnology company based in Watertown, Massachusetts, is set to make a significant impact at the upcoming PEGS Boston Summit and TIDES USA 2024 conferences.

Biopharma PEG, a leading innovator in polyethylene glycol (PEG) derivatives, proudly introduces its featured Azide PEG series, which can be used in drug development, click chemistry, ADCs (Antibody Drug Conjugates), PROTACs (Proteolysis Targeting...

Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development.

Biopharma PEG, a leading provider of innovative solutions for the pharmaceutical industry, is proud to announce an extensive inventory of monodispersed PEGs (Polyethylene Glycols) that cater to a wide range of applications, including Antibody Drug...

Cholesterol, a derivative of cyclopentane polyhydrophenanthrene, is the main steroid compound in mammals. Most of the traditional cholesterol comes from animal brainstem and lanolin, which is of animal origin and has the risk of carrying animal viruses.

Global vaccine development includes a total of 966 vaccine candidates as of January 1, 2023, of which 23% (220) are traditional inactivated or attenuated vaccines.